National Institutes of Health, Public Health Service, HHS.
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.
Human Renal Cell Carcinoma (RCC) Cell Lines Derived From Surgically Removed Tumors
Description of Technology: Scientists at the National Institutes of Health (NIH) have developed three cell lines obtained from renal cell carcinoma (RCC) patients. The cell lines, designated 1581 RCC, 1764 RCC, and 2194 RCC, were derived from human tumor samples surgically resected from patients in the inventors' clinic. Each cell line is human leukocyte antigen-A2 (HLA-A2) negative and expresses a variety of known tumor antigens. The 1764 RCC cell line is known to express the HLA-A3 antigen and high levels of nonmutated fibroblast growth factor 5 (FGF-5). These cell lines can be widely used in molecular biology for various assays and to screen for potential therapeutics with activity against RCC. The RCC cell lines can also serve as negative control samples for HLA-A2 expression.
- Research tools for examining the common and diverse biological and pathological features of RCC from different patients in vitro.
- Research tools for testing the activity of potential anti-cancer drugs against RCC.
- Source for mRNA and protein antigens expressed in kidney cancer.
- Negative control cell lines for HLA-A2 expression in molecular biology.
- Possible starting material for developing a cancer vaccine against RCC.
- Cell lines are derived directly from RCC patient samples: These cell lines are anticipated to retain many features of primary RCC samples. Studies performed using these cell lines may have a direct correlation to the initiation, progression, treatment, and prevention of RCC in humans.Start Printed Page 64701
- Do not express the HLA-A2 allele: A majority of the cancer vaccines and immunotherapies developed to date have focused on utilizing HLA-A2 restricted tumor epitopes since this HLA allele is largely expressed in the human population. However, therapies restricted to HLA-A2 recognition will not be successful in RCC patients that do not express this allele. For these RCC patients, additional therapies are needed that are directed against epitopes presented by different HLA alleles.
Inventors: Ken-ichi Hanada, Qiong J. Wang, James C. Yang (NCI).
Related Publication: K Hanada et al. Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas. Cancer Res. 2001 Jul 15;61(14):5511-5516.
Patent Status: HHS Reference No. E-005-2010/0—Research Tool. Patent protection is not being pursued for this technology.
Licensing Status: Available for licensing under a Biological Materials License Agreement.
Licensing Contact: Samuel E. Bish, Ph.D.; 301-435-5282; firstname.lastname@example.org.
Small-Molecule Inhibitors of Angiogenesis
Description of Technology: Angiogenesis, the growth of new blood vessels from existing vessels, is a normal and vital process in growth and development. Deregulation of angiogenesis plays a role in many human diseases, including cancer, age-related macular degeneration, diabetic retinopathy, and endometriosis.
NCI investigators have used a cell-based high-throughput screening method to identify a set of anti-angiogenic small molecules. These compounds are highly active, inhibiting both endothelial cell growth and tube formation, and are not cytotoxic. Structure-activity relationship analysis has revealed that these compounds are unrelated to known anti-angiogenic compounds, and hence may operate through a novel mechanism of action. Thus, these compounds would be promising candidates for the development of new anti-angiogenesis therapeutics.
Applications: Development of new anti-angiogenesis therapeutics.
Advantages: These compounds are structurally unrelated to other known anti-angiogenesis compounds, and exhibit high activity without cytotoxicity.
Development Status: In vivo studies using xenograft models are underway.
Inventors: Enrique Zudaire Ubani et al. (NCI).
Publication: In preparation.
Patent Status: HHS Reference No. E-263-2009/0—U.S. Provisional Application No. 61/230,667 filed 31 Jul 2009.
Related Technology: HHS Reference No. E-281-2007/0—Multicolored Fluorescent Cell Lines for High-Throughput Angiogenesis and Cytotoxicity Screening.
Licensing Status: Available for licensing.
Licensing Contact: Tara Kirby, Ph.D.; 301-435-4426; email@example.com.
Collaborative Research Opportunity: The National Cancer Institute Angiogenesis Core Facility is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a new set of non-cytotoxic antiangiogenic small molecules. Please contact John D. Hewes, Ph.D. at 301-435-3121 or firstname.lastname@example.org for more information.
Identification of Colorectal Cancer Biomarkers by Serum Protein Profiling
Description of Technology: This invention describes serum features that distinguish colorectal carcinoma malignant patient samples versus healthy samples using surface-enhanced laser desorption ionization time-of-flight (SELDI-TOF) mass spectrometry. By comparing healthy versus malignant samples, the investigators were able to identify thirteen (13) serum features that have been validated using an independently collected, blinded validation set of 55 sera samples. The features are characterized by the mass to charge ratio (m/z ratio). The investigators have shown that SELDI-TOF based serum marker protein profiling enables minimally invasive detection of colon cancer with 96.7 percent sensitivity and 100 percent specificity.
Colorectal cancer is the third most common cancer and the third leading cause of cancer-related mortality in the United States. Current diagnostic methods for colorectal cancer have a large non-compliance rate because of discomfort, e.g., sigmoidoscopy or colonoscopy, or have a high rate of false positive results, e.g., fecal occult blood tests. The claimed invention has the potential to be a widely used, easy-to-use, and inexpensive diagnostic.
Inventors: Thomas Ried and Jens Habermann (NCI).
Patent Status: U.S. Patent Application No. 11/886,886 filed 21 Sep 2007 (HHS Reference No. E-106-2005/0-US-03).
Licensing Status: Available for licensing.
Licensing Contact: Surekha Vathyam, Ph.D.; 301-435-4076; email@example.com.Start Signature
Dated: December 2, 2009.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.
[FR Doc. E9-29250 Filed 12-7-09; 8:45 am]
BILLING CODE 4140-01-P